The latest market price and purchasing reference of canafenib/encofenib

Encorafenib (Encorafenib) is an oral targeted anti-cancer drug mainly used to treat patients with advanced melanoma associated with BRAF V600 mutations. At present, canafenib has just been approved for marketing in China, so it is still difficult to purchase it directly from domestic pharmacies or hospitals. Patients need to consult professional channels for specific accessibility. Due to the short time on the market, domestic prices are not yet completely transparent. Patients should learn more about the relevant costs and medical insurance policies before using it.

In overseas markets, the original drug of canafenib is mainly the European version, with common specifications of 75 mg According to the latest market information, the price of 75 mg Due to the influence of exchange rates and sales channels, the specific price will fluctuate, which makes the original drug more economically burdensome, especially for patients who take the drug for a long time.

In comparison, the generic version of canafenib is more advantageous in terms of price. The Lao version of generic drugs has been launched in overseas markets. The price per box is about 4,000 yuan. The ingredients of the drugs are basically the same as the original drugs, which can provide patients with a more economical choice. This type of generic drugs relieves patients' financial pressure to a certain extent, but when purchasing, you still need to pay attention to formal channels and drug quality to ensure drug safety and efficacy.

Overall, Canafenib is still in its early stages in the domestic market, with limited purchase channels and high prices. Overseas original drugs are expensive, while generic drugs in countries such as Laos are more affordable. When choosing medication, patients should comprehensively consider the source, price, efficacy and their own condition, work with their attending doctor to formulate the most suitable treatment plan, and purchase drugs through formal channels to ensure safety and therapeutic effect.

Reference materials:https://www.drugs.com/